SCHEMBL22016877

SCHEMBL22016877

CC(C)n1c(=O)c2ccncc2n(C)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.41
ADORA2A P29274 2/20 0.41
ADORA1 P30542 1/20 0.41
AAK1 Q2M2I8 3/20 0.41
NFATC1 O95644 2/20 0.41
GSK3B P49841 2/20 0.41
DYRK1A Q13627 2/20 0.41
METAP2 P50579 1/20 0.40
ROCK2 O75116 1/20 0.38
ADORA2B P29275 1/20 0.38
HPD P32754 2/20 0.38
KDM5A P29375 1/20 0.38
PLK1 P53350 1/20 0.36
KAT2B Q92831 2/20 0.36
CMA1 P23946 2/20 0.36
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
USP2 O75604 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22017691 0.87 GRM4 (0.44) ADORA3ADORA2AADORA1METAP2ADORA2B
SCHEMBL22016876 0.87 AAK1 (0.40) ADORA3ADORA2AADORA1AAK1DYRK1A
SCHEMBL22016873 0.84 AAK1 (0.39) ADORA3ADORA2AADORA1AAK1DYRK1A
SCHEMBL13322657 0.83 MAPK14 (0.40) ADORA3ADORA2AADORA1NFATC1GSK3B
SCHEMBL13322656 0.83 HPD (0.42) ADORA3ADORA2AADORA1NFATC1GSK3B
SCHEMBL13819107 0.83 ADORA3 (0.53) ADORA3ADORA2AADORA1AAK1NFATC1
SCHEMBL24437016 0.78 CMA1 (0.38) ADORA3ADORA2AADORA1AAK1KDM5A
SCHEMBL22016215 0.78 CMA1 (0.38) ADORA3ADORA2AADORA1AAK1KDM5A
SCHEMBL22016239 0.76 ADORA3 (0.43) ADORA3ADORA2AADORA1AAK1NFATC1
SCHEMBL16352662 0.76 ERCC1 (0.61) PLK1ERCC1FEN1ERCC4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023220741-A1 ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF DICE MOLECULES SV, INC. (US) 2023-11-16 WO disclosed
US-20230041518-A1 QUINOLINE DERIVATIVES GILEAD SCIENCES, INC. 2023-02-09 US disclosed
US-20220152014-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. (US) 2022-05-19 US disclosed
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS GILEAD SCIENCES, INC. 2022-04-21 US disclosed
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin GILEAD SCIENCES, INC. (US) 2022-01-18 US disclosed
US-11174256-B2 Imidazopyridine derivatives GILEAD SCIENCES, INC. (US) 2021-11-16 US disclosed
US-11116760-B2 Quinoline derivatives GILEAD SCIENCES, INC. (US) 2021-09-14 US disclosed
US-20200165248-A1 IMIDAZOPYRIDINE DERIVATIVES GILEAD SCIENCES, INC. 2020-05-28 US disclosed
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. 2020-05-21 US disclosed
US-20200155538-A1 QUINOLINE DERIVATIVES GILEAD SCIENCES, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041518-A1 QUINOLINE DERIVATIVES CFTR, NQO1, IRF3 ADORA3 1752/4885ADORA2A 1362/4885ADORA1 1182/4885
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN ITGB7, ITGB4, ITGA4 ADORA3 2207/4885ADORA2A 2997/4885ADORA1 1692/4885
US-20200155538-A1 QUINOLINE DERIVATIVES CFTR, NQO1, IRF3 ADORA3 1752/4885ADORA2A 1362/4885ADORA1 1182/4885
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin ITGB7, ITGB4, ITGA4 ADORA3 2207/4885ADORA2A 2997/4885ADORA1 1692/4885
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS ITGB7, ITGB1, ITGA2B ADORA3 1388/4885ADORA2A 2215/4885ADORA1 1200/4885
US-11174256-B2 Imidazopyridine derivatives TPMT, IRAK4, CFTR ADORA3 1098/4885ADORA2A 1178/4885ADORA1 943/4885
US-20220152014-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN ITGB7, ITGB4, ITGA4 ADORA3 2207/4885ADORA2A 2997/4885ADORA1 1692/4885
US-11116760-B2 Quinoline derivatives CFTR, NQO1, IRF3 ADORA3 1752/4885ADORA2A 1362/4885ADORA1 1182/4885
US-20200165248-A1 IMIDAZOPYRIDINE DERIVATIVES TPMT, IRAK4, CFTR ADORA3 1098/4885ADORA2A 1178/4885ADORA1 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.